• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期软组织肉瘤的症状负担、生存情况及姑息治疗

Symptom burden, survival and palliative care in advanced soft tissue sarcoma.

作者信息

Gough Nicholas J, Smith Clare, Ross Joy R, Riley Julia, Judson Ian

机构信息

Palliative Care Department, Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK.

出版信息

Sarcoma. 2011;2011:325189. doi: 10.1155/2011/325189. Epub 2011 Dec 11.

DOI:10.1155/2011/325189
PMID:22190862
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3236373/
Abstract

Introduction. The symptom burden and role of palliative care (PC) in patients with advanced soft tissue sarcoma (STS) are not well defined. Methods. This study retrospectively reviewed both symptoms and PC involvement in patients known to an STS referral centre who died in one calendar year. Results. 81 patients met inclusion criteria of which 27% had locally advanced disease and 73% metastases at initial referral. The median number of symptoms was slowly progressive ranging from 2 (range 0-5) before first-line chemotherapy (n = 50) to 3 (range 1-6) at the time of best supportive care (BSC) decision (n = 48). Pain and dyspnoea were the commonest symptoms. Median overall survival from BSC decision was 3.4 weeks. 88% had PC involvement (either hospital, community, or both) with median time from first PC referral to death of 16 (range 0-110) weeks. Conclusions. Patients with metastatic STS have a significant symptom burden which justifies early PC referral. Pain, including neuropathic pain, is a significant problem. Dyspnoea is common, progressive and appears to be undertreated. Time from BSC decision to death is short, and prospective studies are required to determine whether this is due to overtreatment or very rapid terminal disease progression.

摘要

引言。晚期软组织肉瘤(STS)患者的症状负担及姑息治疗(PC)的作用尚不明确。方法。本研究回顾性分析了一家STS转诊中心在一个日历年中死亡患者的症状及PC参与情况。结果。81例患者符合纳入标准,其中27%在初次转诊时为局部晚期疾病,73%有转移。症状数量中位数呈缓慢进展,从一线化疗前的2个(范围0 - 5个,n = 50)增至最佳支持治疗(BSC)决策时的3个(范围1 - 6个,n = 48)。疼痛和呼吸困难是最常见的症状。从BSC决策起的中位总生存期为3.4周。88%的患者接受了PC治疗(包括医院、社区或两者),从首次PC转诊到死亡的中位时间为16周(范围0 - 110周)。结论。转移性STS患者有显著的症状负担,这证明应尽早转诊至PC治疗。疼痛,包括神经性疼痛,是一个重大问题。呼吸困难常见、呈进行性且似乎未得到充分治疗。从BSC决策到死亡的时间很短,需要进行前瞻性研究以确定这是由于过度治疗还是终末期疾病进展非常迅速所致。

相似文献

1
Symptom burden, survival and palliative care in advanced soft tissue sarcoma.晚期软组织肉瘤的症状负担、生存情况及姑息治疗
Sarcoma. 2011;2011:325189. doi: 10.1155/2011/325189. Epub 2011 Dec 11.
2
Symptom Burden in Advanced Soft-Tissue Sarcoma.晚期软组织肉瘤的症状负担
J Pain Symptom Manage. 2017 Mar;53(3):588-597. doi: 10.1016/j.jpainsymman.2016.10.357. Epub 2016 Dec 29.
3
Impact of a specialised palliative care intervention in patients with advanced soft tissue sarcoma - a single-centre retrospective analysis.晚期软组织肉瘤患者接受专业姑息治疗干预的影响 - 单中心回顾性分析。
BMC Palliat Care. 2021 Jan 14;20(1):16. doi: 10.1186/s12904-020-00702-1.
4
The Magnitude and Effects of Early Integration of Palliative Care Into Oncology Service Among Adult Advanced Cancer Patients at a Tertiary Care Hospital.三级护理医院成年晚期癌症患者姑息治疗早期融入肿瘤服务的规模及效果
Cureus. 2021 May 29;13(5):e15313. doi: 10.7759/cureus.15313.
5
A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial.一项比较 trabectedin 与最佳支持治疗在预治疗软组织肉瘤患者中的随机 III 期临床试验:T-SAR,一项法国肉瘤研究组的研究。
Ann Oncol. 2021 Aug;32(8):1034-1044. doi: 10.1016/j.annonc.2021.04.014. Epub 2021 Apr 29.
6
Symptom Burden and End-of-Life Palliative Treatments during the Last Two Weeks of Life in Patients with Advanced Musculoskeletal Sarcoma.晚期肌肉骨骼肉瘤患者生命最后两周的症状负担和临终姑息治疗。
J Palliat Med. 2019 Aug;22(8):908-914. doi: 10.1089/jpm.2018.0415. Epub 2019 Feb 14.
7
Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.12 项 EORTC 软组织和骨肿瘤研究组的一线化疗治疗老年晚期软组织肉瘤患者的结果:汇总分析。
Oncologist. 2018 Oct;23(10):1250-1259. doi: 10.1634/theoncologist.2017-0598. Epub 2018 Apr 12.
8
Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.一线姑息化疗对晚期软组织肉瘤的显著临床益处:488例患者的回顾性分析及预后因素鉴定
Cancer. 2008 Apr 1;112(7):1585-91. doi: 10.1002/cncr.23332.
9
Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways.门诊姑息治疗和胸部肿瘤内科:转诊标准和临床护理路径。
Lung Cancer. 2020 Jan;139:13-17. doi: 10.1016/j.lungcan.2019.10.003. Epub 2019 Oct 11.
10
Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study.远处转移与软组织肉瘤局部晚期疾病的预后相关性:EORTC-STBSG 数据库研究。
Eur J Cancer. 2018 May;94:187-198. doi: 10.1016/j.ejca.2018.02.015. Epub 2018 Mar 22.

引用本文的文献

1
Patient-Reported Outcome Measurement and Reporting for Patients with Soft Tissue Tumors: A Scoping Literature Review.软组织肿瘤患者的患者报告结局测量与报告:一项范围界定文献综述
Cancers (Basel). 2025 Jul 9;17(14):2280. doi: 10.3390/cancers17142280.
2
Palliative care outpatient interventions to limit aggressive care at end-of-life for patients with advanced soft tissue sarcomas.姑息治疗门诊干预措施,以限制晚期软组织肉瘤患者临终时的积极治疗。
Support Care Cancer. 2025 Apr 16;33(5):389. doi: 10.1007/s00520-025-09455-0.
3
Patient-physician agreement on function and pain is associated with long-term outcomes in sarcoma: findings from a longitudinal study.

本文引用的文献

1
England's approach to improving end-of-life care: a strategy for honoring patients' choices.英国改善临终关怀的方法:尊重患者选择的策略。
Issue Brief (Commonw Fund). 2011 Jul;15:1-15.
2
Access to palliative care services in hospital: a matter of being in the right hospital. Hospital charts study in a Canadian city.在医院获得姑息治疗服务:关键在于选择合适的医院。加拿大某城市的医院图表研究。
Palliat Med. 2012 Jan;26(1):89-94. doi: 10.1177/0269216311408992. Epub 2011 Jun 16.
3
The prevalence of pain in patients attending sarcoma outpatient clinics.
患者与医生就功能和疼痛达成的共识与肉瘤的长期预后相关:一项纵向研究的结果
J Cancer Surviv. 2025 Feb;19(1):376-385. doi: 10.1007/s11764-023-01473-3. Epub 2023 Oct 17.
4
A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients' Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece.一项多中心、前瞻性、观察性研究,旨在评估在希腊真实世界环境中接受曲贝替定治疗的晚期软组织肉瘤患者的临床活性及其对症状负担和患者生活质量的影响。
Cancers (Basel). 2022 Apr 8;14(8):1879. doi: 10.3390/cancers14081879.
5
Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: baseline results from the HOLISTIC study.晚期软组织肉瘤患者开始姑息化疗的优先事项和偏好:HOLLISTIC 研究的基线结果。
ESMO Open. 2021 Oct;6(5):100258. doi: 10.1016/j.esmoop.2021.100258. Epub 2021 Sep 9.
6
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.在晚期去分化脂肪肉瘤患者中,selinexor 与健康相关的生活质量和疼痛。
Future Oncol. 2021 Aug;17(22):2923-2939. doi: 10.2217/fon-2021-0284. Epub 2021 Apr 15.
7
Impact of a specialised palliative care intervention in patients with advanced soft tissue sarcoma - a single-centre retrospective analysis.晚期软组织肉瘤患者接受专业姑息治疗干预的影响 - 单中心回顾性分析。
BMC Palliat Care. 2021 Jan 14;20(1):16. doi: 10.1186/s12904-020-00702-1.
8
Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center.曲贝替定联合放疗治疗晚期软组织肉瘤:在一家肉瘤参考中心治疗40例患者的经验
Cancers (Basel). 2020 Dec 12;12(12):3740. doi: 10.3390/cancers12123740.
9
The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany-Cross-Sectional Results of a Nationwide Observational Study (PROSa).德国肉瘤患者及幸存者的健康相关生活质量——一项全国性观察性研究(PROSa)的横断面结果
Cancers (Basel). 2020 Nov 30;12(12):3590. doi: 10.3390/cancers12123590.
10
Psychological adaptation and recovery in youth with sarcoma: a qualitative study with practical implications for clinical care and research.肉瘤青年患者的心理适应与康复:一项对临床护理和研究具有实际意义的定性研究
BMJ Open. 2020 Nov 23;10(11):e038799. doi: 10.1136/bmjopen-2020-038799.
肉瘤门诊患者的疼痛患病率。
Sarcoma. 2011;2011:813483. doi: 10.1155/2011/813483. Epub 2011 May 5.
4
Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study.体能状态是晚期软组织肉瘤患者早期死亡的最强风险因素:欧洲癌症研究与治疗组织软组织和骨肉瘤研究组(STBSG)和法国肉瘤研究组(FSG)研究。
Br J Cancer. 2011 May 10;104(10):1544-50. doi: 10.1038/bjc.2011.136. Epub 2011 Apr 19.
5
Early palliative care for patients with metastatic non-small-cell lung cancer.转移性非小细胞肺癌患者的早期姑息治疗。
N Engl J Med. 2010 Aug 19;363(8):733-42. doi: 10.1056/NEJMoa1000678.
6
Guidelines for the management of soft tissue sarcomas.软组织肉瘤管理指南。
Sarcoma. 2010;2010:506182. doi: 10.1155/2010/506182. Epub 2010 May 31.
7
Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma.晚期软组织肉瘤二线姑息化疗的临床获益
Sarcoma. 2010;2010:264360. doi: 10.1155/2010/264360. Epub 2010 May 20.
8
Barriers to the development of palliative care in the countries of Central and Eastern Europe and the Commonwealth of Independent States.中欧和东欧国家以及独立国家联合体姑息治疗发展的障碍。
J Pain Symptom Manage. 2009 Mar;37(3):305-15. doi: 10.1016/j.jpainsymman.2008.03.011.
9
Variability in access to hospital palliative care in the United States.美国医院姑息治疗可及性的差异。
J Palliat Med. 2008 Oct;11(8):1094-102. doi: 10.1089/jpm.2008.0053.
10
Effectiveness of specialized palliative care: a systematic review.专科姑息治疗的有效性:一项系统评价。
JAMA. 2008 Apr 9;299(14):1698-709. doi: 10.1001/jama.299.14.1698.